Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.73 USD | -6.51% | -9.60% | +103.73% |
May. 07 | Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 192M |
---|---|---|---|---|---|
Net income 2024 * | -43M | Net income 2025 * | -53M | EV / Sales 2024 * | - |
Net cash position 2024 * | 107M | Net cash position 2025 * | 188M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.39
x | P/E ratio 2025 * |
-5.93
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.65% |
Latest transcript on Trevi Therapeutics, Inc.
1 day | -6.51% | ||
1 week | -9.60% | ||
Current month | -6.83% | ||
3 months | +66.46% | ||
6 months | +108.40% | ||
Current year | +103.73% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Thomas Sciascia
FOU | Founder | 70 | 10-12-31 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 21-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 18-10-09 |
James Cassella
BRD | Director/Board Member | 69 | 20-02-12 |
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 2.73 | -6.51% | 89,429 |
24-05-09 | 2.92 | +10.61% | 259,175 |
24-05-08 | 2.64 | -8.97% | 116,736 |
24-05-07 | 2.9 | -1.36% | 81,887 |
24-05-06 | 2.94 | -2.65% | 46,713 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+103.73% | 192M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- TRVI Stock